← Eichor
Condition: Msi H Dmmr Solid Tumors Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Msi H Dmmr Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With H
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770102AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Phase 1 · 22 location(s) · Amgen · NCT07403721KN035 for dMMR/MSI-H Advanced Solid Tumors
Phase 2 · 1 location(s) · 3D Medicines (Sichuan) Co., Ltd. · NCT03667170Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 · 30 location(s) · BeiGene · NCT03736889A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Phase 1 · 1 location(s) · Jemincare · NCT07208136A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer
Phase 1/Phase 2 · 22 location(s) · GlaxoSmithKline · NCT07213609Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/Phase 2 · 7 location(s) · Neonc Technologies, Inc. · NCT06047379A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Phase 2 · 1 location(s) · Fudan University · NCT07003022EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combinatio
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT07262619Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Phase N/A · 8 location(s) · Elephas · NCT07327489Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 15 location(s) · MOMA Therapeutics · NCT06974110
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.